Nuclear medicine in the assessment of differentiated thyroid cancer.
Despite modern multi-modality treatment, 10-30% of patients treated for differentiated thyroid cancer (DTC) ultimately develop local recurrence or metastatic disease. These malignancies are frequently slow-growing and secondary surgical resection is often undertaken along with radioactive iodine treatment. Correlation of radiological imaging with nuclear medicine studies is essential for individualized treatment planning, and to optimize this management. Radiologists should be familiar with the interpretation of various nuclear medicine studies used to image differentiated thyroid neoplasms.
Rutherford
G-C
GC
Nuclear Medicine Department, Nottingham City Hospital, Nottingham, UK. gaylerutherford@doctors.org.uk
Franc
B
B
O'Connor
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal; D003287:Contrast Media; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015282:Octreotide; D049268:Positron-Emission Tomography / Q000379:methods; D011877:Radionuclide Imaging / Q000379:methods; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D013965:Thyroidectomy; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods; D014057:Tomography, X-Ray Computed / Q000379:methods; D051598:Whole Body Imaging
D018931:Antineoplastic Agents, Hormonal; D003287:Contrast Media; D007457:Iodine Radioisotopes; D019788:Fluorodeoxyglucose F18; D013954:Thyroglobulin; D015282:Octreotide